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ELIOT CORDAY, MD, FACC, HEINRICH R. SCHELBERT, MD, FACC 
Los Angeles, California 
Positron emission tomography was used to image blood flow and 
metabolic tracers in risk zone myocardium after left anterior de-
scending coronary artery occlusion during synchronized coronary 
venous retroperfusion. Six control and seven intervention open chest 
dogs had occlusion of the mid left anterior descending coronary 
artery. Synchronized retroperfusion commenced 25 min later. Flow 
tracers (rubidium-82 and nitrogen-13 ammonia) were injected ret-
rogradely. Three hours after coronary occlusion, fluorine-18 (F-18) 
deoxyglucose uptake in the control and treatment groups was 
compared. At 200 min of occlusion, infarct size was assessed. 
Retrograde flow tracer uptake was observed in the risk zone in 
the seven intervention dogs. Fluorine-18 deoxyglucose uptake in 
the risk zone was increased in five of the six intervention dogs but 
was reduced in five of the six control dogs. The risk zone to normal 
zone F -18 deoxyglucose count ratio was higher in the intervention 
Synchronized coronary venous retroperfusion has been 
shown (1-6) to support ischemic myocardium using im-
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than the control group (1.13 ± 0.39 vs. 0.59 ± 0.51; p < 0.05). 
The endocardial subsegment risk zone to normal zone F -18 
deoxyglucose count ratio was also significantly higher in the 
intervention group. Percent infarction in the risk zone was 70% 
lower in the group treated with synchronized retroperfusion than 
in the control group (18.4 ± 22.6% vs. 61.2 ± 25.4%; p < 0.02). 
Thus, positron emission tomography revealed that retroperfu-
sion could deliver oxygenated blood and maintain metabolism in 
risk zone myocardium. Infarct size was limited to 30% of that of 
control. In acute closure of the left anterior descending coronary 
artery, synchronized retroperfusion might be considered for 
maintaining viability of the jeopardized myocardium if the artery 
cannot be reopened rapidly. 
(J Am Coil CardioI1991;18:257-70) 
provement in regional wall motion and limitation of infarct 
size as end points. Therefore, it is a potential therapeutic 
approach in the management of acute coronary artery occlu-
sion, especially when the artery cannot be reopened rapidly. 
However, there is uncertainty about how synchronized 
retroperfusion might achieve its effects. Retrograde delivery 
of blood toward ischemic myocardium in acute coronary 
artery occlusion during retroperfusion has been demon-
strated in vivo with Renografin (diatrizoate) 0), radioactive 
microspheres (7), digital subtraction angiography (8) and in 
vitro with monastral blue (9). However, delivery of nutrient 
flow at the cellular level of the myocardium in vivo has not 
been clearly demonstrated. As a result, speculation has 
focused on the role of collateral flow development as an 
explanation for the apparent benefit of synchronized retro-
perfusion. Positron emission tomography using diffusible 
tracers of blood flow and metabolism has the ability to image 
myocardial blood flow and metabolism at the cellular level. 
Together with the relatively short physical half-life of 
positron-emitting isotopes, which allows repeat studies dur-
ing interventions, positron emission tomography offers the 
potential of examining the concept of retroperfusion in a 
unique way. 
The purpose of this study was to examine in short-term 
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dog experiments the in vivo efficacy of synchronized retro-
perfusion on myocardial salvage using positron emission 
tomography of myocardial blood flow and glucose metabo-
lism to 1) assess retrograde delivery of a diffusible tracer to 
the ischemic myocardium, 2) determine glucose uptake in 
the ischemic myocardium, and 3) correlate these findings 
with the potential effect of synchronized retroperfusion on 
infarct size limitation. 
Methods 
Animal preparation, Twenty-one mongrel dogs were 
used. After sedation with intramuscular morphine (30 mg), 
the dogs were anesthetized with intravenous thiamylal 
(30 mg/kg body weight), intubated and ventilated with a 
Harvard respirator. Additional thiamylal was given as 
needed to maintain anesthesia. Catheters for venous access, 
measurement of aortic pressure and withdrawal of arterial 
blood were inserted into the right femoral vein and right and 
left femoral arteries. Electrocardiographic (ECG) electrodes 
were attached to the four limbs of the dogs for monitoring 
cardiac rhythm. The dogs were assigned to either a control 
or a treatment group. 
In the treatment group, an autoinflatable balloon-tipped 
coronary sinus catheter was placed in the coronary sinus 
under fluoroscopic guidance (4). The coronary sinus catheter 
was inserted through the left internal jugular vein into the 
coronary sinus and advanced to the great cardiac vein. 
Adequate catheter positioning was assisted by injection of 
Renografin. Positioning of the end of the catheter as distally 
as possible within the great cardiac vein or the anterior 
interventricular vein was such as to permit pumping in 
diastole and ready efflux of dye during cardiac systole to 
allow for adequate venous drainage. After insertion of the 
coronary sinus catheter, the dog received heparin (200 U/kg 
body weight). Coronary sinus pressure was measured 
through a separate channel in the catheter in all but the first 
two of the treatment dogs. An 8F cannula was placed in a 
carotid artery for withdrawal of arterial blood for the retro-
perfusion pump. 
In both the treatment and the control group, a left 
thoracotomy was performed. The pericardium was opened 
widely and anchored to the chest wall, forming a cradle in 
which the heart was suspended. The mid-portion of the left 
anterior descending coronary artery was dissected free and a 
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Figure 1. Experimental protocol (see 
text for description). FDG = fluorine-
18 deoxyglucose; IV = intravenously; 
LAD = left anterior descending coro-
nary artery; MBF = myocardial blood 
flow; PET = positron emission tomogra-
phy; SRP = synchronized retroperfu-
sion; JL = radioactive microspheres. 
snare was loosely placed around it. A catheter was inserted 
through the left atrial appendage into the left atrium for the 
administration of radioactive microspheres. All dogs in the 
control group also received heparin (200 U/kg body weight) 
after instrumentation. The instrumented dogs were trans-
ferred to the imaging suite, where anesthesia was changed to 
and maintained with halothane inhalation. 
Experimental protocol, After the dog was placed in the 
positron emission tomograph (ECAT III, CTI), a transmis-
sion scan was acquired for photon attenuation correction 
and accurate positioning of the heart within the three imag-
ing planes. The image planes were oriented perpendicular to 
the long axis of the left ventricle to obtain short-axis views of 
the ventricle. Cross-sectional emission images were ac-
quired 3 min after anterograde or retrograde administration 
of rubidium-82 or nitrogen-13 (N-13) ammonia (both 
positron-emitting tracers of blood flow) and 45 min after 
intravenous injection of fluorine-18 (F-18) deoxyglucose (a 
positron-emitting tracer of glucose metabolism). The recon-
structed images were usually available for visual inspection 
within 10 min of image acquisition. 
Figure 1 schematically outlines the study protocol. Be-
fore occlusion of the left anterior descending coronary 
artery, a positron-emitting tracer of blood flow and radioac-
tive micro spheres (10) were coinjected into the left atrium to 
define anterograde myocardial blood flow at control study. A 
bolus injection of lidocaine (2 mg/kg) was administered 
intravenously 2 min before coronary artery occlusion. Fif-
teen minutes after the occlusion, the flow tracer and radio-
active microspheres were again injected to delineate antero-
grade blood flow to the risk zone on the tomographic images 
and to measure regional myocardial blood flow. Twenty to 
30 min after coronary occlusion, synchronized retroperfu-
sion was started in the treatment group. Retroperfusion flow 
was started at 40 mUmin and gradually increased until the 
coronary sinus diastolic pressure reached ~60 mm Hg. 
Pump flow was measured with a calibrated in-line electro-
magnetic flow meter. Retrograde blood flow was then eval-
uated with a positron-emitting tracer of blood flow adminis-
tered through an injection port on the outlet of the 
retroperfusion pump. Review of the resulting images allowed 
assessment of the presence and adequacy of retroperfusion 
in the risk zone. If retroperfusion of the risk zone was 
inadequate, the catheter position was adjusted and retro-
grade flow was increased. Depending on availability of 
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radiotracers, retrograde injections of the flow tracer were 
repeated to assess retroperfusion of the risk zone. 
At 100 min after occlusion, a positron-emitting flow tracer 
was injected to reexamine anterograde blood flow to the risk 
zone. At 120 min after occlusion, radioactive microspheres 
were administered through the left atrium and F-18 deoxy-
glucose was injected intravenously. Forty minutes was al-
lowed for tracer clearance from blood and metabolic trap-
ping of the tracer in the myocardium. Fluorine-18 
deoxyglucose images were then acquired for 10 min at 160 to 
170 min after coronary occlusion. 
Arterial blood samples were obtained for determination 
of plasma concentrations of glucose, lactate and free fatty 
acids before and 15 min after the coronary ligation and at the 
time of the F-18 deoxyglucose injection. 
Preparation of myocardial cross sections. At 200 min of 
left anterior descending coronary artery occlusion, the heart 
was arrested with concentrated potassium chloride solution 
and excised and the risk area distal to the site of the snare 
occluder identified. The heart was then sliced into at least 
three but usually five contiguous 1 cm thick short-axis cross 
sections. Slices 1, 3 and 5 were placed on a firm board and 
their outlines traced on clear acetate paper. They were then 
immersed in a triphenyltetrazolium chloride bath for 15 min. 
After removal from the triphenyltetrazolium chloride bath, 
the myocardial slices were again placed on clear acetate 
paper to delineate the area of triphenyltetrazolium chloride 
nonstaining and then photographed. The acetate sheet out-
lines were used to determine by planimetry the areas of risk 
and the normal zones. Slices 2 and 4 were immediately 
placed in Carnoy's fixative and subsequently stained with 
periodic acid-Schiff to define the area of glycogen depletion. 
The retroperfusion system. The retroperfusion system 
consisted of an ECG-gated pump connected to a coronary 
sinus catheter as described previously (4). The pump was a 
positive displacement piston pump operated by a stepper 
motor. The stroke volume was adjusted with a microproces-
sor and was proportional to the desired flow and heart rate. 
Pumping was synchronous to the R wave of the ECG with a 
built-in delay so that pumping occurred only in diastole. The 
downstroke of the pump was active and ensured deflation of 
the balloon in the coronary sinus catheter to allow for 
unobstructed drainage of coronary sinus blood into the right 
atrium during systole. 
The coronary sinus catheter had two channels. The first 
channel was a combined pumping and balloon inflation 
channel. As pumping started, the balloon was automatically 
inflated. Then as the pump stroke continued, blood was 
pumped out of the end of the catheter. The second channel 
allowed continuous monitoring of pressure within the coro-
nary smus. 
Positron-emitting tracers of blood ftow and glucose utiliza-
tion. Regional myocardial blood flow was evaluated with 
either N-13 ammonia (11,12) or, if available, rubidium-82 
(13). Nitrogen-13 ammonia (5 to 10 mCi) or rubidium-82 (5 to 
10 mCi) was injected intravenously to delineate the risk area 
O'BYRNE ET AL. 259 
POSITRON TOMOGRAPHY OF RETROPERFUSION 
on the positron emission tomographic images after occlusion 
of the left anterior descending coronary artery. To evaluate 
the efficacy of retrograde delivery of blood flow, the same 
flow tracer (usually 5 to 10 mCi) was injected through the 
retroperfusion pump into the coronary sinus catheter. For 
repeat imaging studies, sufficient time for physical decay was 
allowed (usually 10 min for rubidium-82 and 30 min for N-13 
ammonia). Except for one dog, either rubidium-82 or N-13 
ammonia was used in a given animal. Regional myocardial 
utilization of exogenous glucose was evaluated qualitatively 
with F-18 deoxyglucose (14,15). The tracer was injected into 
the left atrium and 40 min was allowed for metabolic trapping 
of tracer in the myocardium and clearance from blood. 
Fluorine-18 deoxyglucose was produced by the method of 
Bida et al. (16) and N-13 ammonia by the method of 
Vaalburg et al. (17). Specific activities of N-13 ammonia 
were 150 to 200 Cilmmol; of F-18 2-fluoro-2-deoxyglucose, 
they were 2 Cilmmol, with radiochemical purities >99%. 
Rubidium-82 was obtained from a strontium-82/rubidium-82 
generator system (Squibb Diagnostics). 
Measurement of regional myocardial blood ftow. Regional 
myocardial blood flow was measured with radioactive mi-
crospheres and the arterial reference sampling technique as 
described previously (10). Carbonized polystyrene micro-
spheres (15 ± 5 pm in diameter, 3M Company, Nuclear 
Products) labeled with scandium-46, strontium-85, selenium-
113, niobium-95 or ruthenium-103 were suspended in 10% 
dextran with 1 drop of Tween-80 (to prevent clumping), 
mixed with a vortex shaker and suspended by ultrasonifica-
tion before injection. One to 2 million microspheres were 
injected into the left atrium, while arterial blood was with-
drawn at a constant rate of 7.8 mllmin for 2.6 min. The total 
microsphere radioactivity in the arterial blood sample and 
microsphere radioactivity concentrations in myocardial tis-
sue samples were determined in a gamma well counter. 
Regional myocardial blood flow was determined from myo-
cardial radioactivity concentrations, the withdrawal rate of 
arterial blood and total activity in the arterial blood sample 
(10). 
Analysis of positron emission tomographic images. Visual 
analysis. The cross-sectional images of myocardial blood 
flow and glucose utilization were evaluated for regional 
decreases or increases in myocardial tracer uptake. Myocar-
dium at risk was defined as myocardium with segmentally 
reduced tracer uptake of either N-13 ammonia or rubidium-
82. In the intervention experiments, the risk zone was 
evaluated for selective retention of retrogradely delivered 
flow tracers as shown by segmental increases in tracer 
activity. The uptake of F-18 deoxyglucose in the risk zone 
was graded as less than, equal to or greater than that of the 
normal zone myocardium. 
Quantitative analysis. The cross-sectional tomographic 
images of the heart were further submitted to circumferential 
activity profile analysis utilizing an operator-interactive pro-
gram (18) on a VAX 780 computer. The program employs an 
edge detection algorithm and automatically delineates the 
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inner and outer boundaries of the left ventricular myocar-
dium. Segments with absent or inadequate tracer uptake 
were included in the left ventricular slice profile by interpo-
lating the inner and outer boundaries of the nearest normal 
myocardium. The circumferential profile analysis began next 
to the interventricular septum at the medial margin of the 
observed risk zone. The ventricular circumference was 
divided into 60 sectors of 6° each, proceeding in a clockwise 
direction from the starting point. Maximal activity in each 
sector was normalized to the highest activity in the circum-
ferential profile and displayed as a function of the angle 
about the ventricular short axis. Mean counts in the risk 
zone and normal myocardium were calculated by averaging 
the mean counts for each 6° sector in the risk zone and 
normal myocardium. The mean risk zone counts were ex-
pressed as a ratio of the mean normal zone counts for flow 
tracer and F-18 deoxyglucose uptake and were compared 
between the two study groups. In addition, in the treatment 
group, flow tracer uptake in the risk zone during retroperfu-
sion was compared with uptake in the risk zone after 
occlusion. This was done by comparing the risk zone and 
normal zone count ratios obtained from the images after 
occlusion and during retroperfusion. 
Postmortem analysis of myocardial cross sections. After 
the myocardial cross sections had been outlined on the 
acetate sheets, slices 1,3 and 5 were cut into sectors, usually 
16 to 30 per slice. Each tissue sample was divided into an 
epicardial and endocardial half, weighing 0.5 to 1 g each, and 
submitted to well counting for determination of radioactivity 
concentrations of radio labeled microspheres and fluorine-18. 
Blood flow was calculated by the arterial reference sample 
technique as described previously (10). 
Tissue samples with flow rates <50% of the mean flow of 
the normal zone in that slice were assigned to the risk zone. 
These subsegments were identified on the acetate sheet map 
of the corresponding myocardial cross section. The risk zone 
was measured by planimetry and expressed as a percent of 
the area of the entire myocardial cross section. The myocar-
dium in slices I, 3 and 5 unstained by triphenyltetrazolium 
chloride was defined as infarcted (19) and its size determined 
by planimetry and expressed as a percent of the entire 
myocardial cross section. Percent infarct size was defined as 
the unstained area relative to the risk zone (that is, myocar-
dium with flow rates <50% of that of normal myocardium). 
The average of the risk zone to normal zone ratios from the 
five slices in the area of myocardium distal to the coronary 
occlusion was used to compare the risk zone, infarct zone 
and percent infarction of the risk zone between the two 
groups. 
Statistics. Values are reported as mean ± SD. Findings in 
the treatment and control groups were analyzed for statisti-
cally significant differences by Student's t test for unpaired 
data. Intragroup comparisons were made with Student's t 
test for paired data. Probability (p) values <0.05 were 
considered significant. 
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Ethics. The dogs were treated and studied in accordance 
with the guidelines of the American Physiological Society 
and of the University of California-Los Angeles Chancel-
lor's Animal Research Committee. 
Results 
Study groups (Table 1). The study included a total of 21 
dogs, II assigned to the treatment group and 10 to the 
control group. However, several dogs were excluded from 
final data analysis because they failed to meet criteria 
considered essential for examining the effects of retroperfu-
sion on acutely ischemic myocardium. These criteria were as 
follows: 1) blood flow in the endocardium distal to the 
coronary occlusion must have decreased by ~50% below 
that in control myocardium to ascertain that the coronary 
occlusion did in fact produce ischemia; 2) the reduction in 
blood flow must have remained constant throughout the 
study period, so that changes in metabolism and tissue 
necrosis could not be attributed to spontaneous reperfusion 
with collateral blood flow; and 3) the coronary sinus catheter 
in the treatment group must have been positioned adequately 
for effective retrograde delivery of blood flow. Table I 
summarizes all dogs studied initially and lists data related to 
their inclusion or exclusion from the study. 
In the control group, coronary occlusion failed to pro-
duce segmental flow defects in Dog CRI and produced only 
a small defect that had resolved on repeat study in Dog CR2. 
In two additional dogs (Dogs CR3 and CR4), blood flow to 
the risk zone was reduced only mildly, suggesting that 
spontaneous reperfusion with collateral blood flow had oc-
curred. Thus, a total of six dogs formed the control group for 
final analysis. 
In the treatment group, four dogs were excluded. Imaging 
could not be performed in Dog TRI because of a scanner 
malfunction and Dog TR2 was withdrawn from study be-
cause of difficulty obtaining an optimal position of the heart 
within the scanner (after repositioning, the flow tracer, N-13 
ammonia [10 min physical half-life] had decayed and pre-
cluded further flow tracer imaging). A third dog (Dog TR3) 
exhibited a malformation of the coronary sinus that appar-
ently precluded adequate retrograde pumping. Contrast ma-
terial injected into the coronary sinus at the time of catheter 
placement showed an apparent cul-de-sac branch at the 
junction of the coronary sinus and the great cardiac vein. 
Necropsy evaluation confirmed a congenital malformation 
that impeded adequate seating of the balloon catheter. A 
fourth dog (Dog TR4) had only a very small perfusion defect 
on the tomographic images distal to the left anterior descend-
ing coronary artery occlusion that would not have allowed 
evaluation of retroperfusion. Thus, a total of seven dogs 
formed the treatment group for final data analysis. 
Hemodynamics (Table 2). Heart rate and blood pressure 
in the control and the treatment groups were compared 
before occlusion, 15 min after occlusion and at the time of 
injection of F-18 deoxyglucose. No differences between 
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Table 1. Risk Zone, Regional Myocardial Blood Flow Ratios and Flow Tracers in All 20 Dogs 
Transmural MBF Ratio Endocardial MBF Ratio 
Dog No. Wt (kg) RZPET Flow Tracer Pre Occl 15 Min Post 120 Min Post Pre Occl 15 Min Post 120 Min Post 
CRI 18.50 Collat Rb 0.96 0.17 0.53 0.95 0.06 0.35 
CR2 19.00 No defect NH3 NoRZ NoRZ NoRZ NoRZ NoRZ NoRZ 
CR3 24.00 Collat NH3 [---------------------None <50%---------------------] [---------------------None <50%---------------------] 
CR4 24.00 Collat NH3 [---------------------None <50%---------------------] [---------------------None <50%---------------------] 
CI 26.50 No scan None 0.91 0.19 0.20 0.77 0.08 0.06 
C2 18.60 Yes NH3 0.70 0.19 0.37 0.71 0.09 0.20 
C3 19.60 Yes NH3 1.04 0.07 0.10 1.02 0.08 0.09 
C4 26.00 Yes NH3 0.84 0.13 0.23 0.75 0.08 0.14 
C5 26.00 Yes NH3 0.44 0.17 0.24 0.46 0.11 0.13 
C6 28.50 Yes NH3 0.99 0.28 0.27 0.74 0.19 0.17 
TRI 38.50 No scan None 1.04 0.43 0.20 0.86 0.11 0.05 
TR2 27.00 Yes NH3 0.93 0.47 0.24 0.35 0.09 0.46 
TR3 28.00 Yes NH3 0.79 0.39 0.38 0.80 0.32 0.28 
TR4 28.00 No defect Rb 0.96 0.81 0.81 0.93 0.80 0.81 
TI 26.00 Yes Rb 0.74 0.17 0.21 0.78 0.11 0.81 
T2 37.00 Yes NH3 0.84 0.19 0.34 0.80 0.18 0.32 
T3 32.00 Yes NH3 0.92 0.20 0.28 0.92 0.11 0.18 
T4 25.00 Yes NH3 0.67 0.38 0.47 0.80 0.39 0.41 
T5 22.00 Yes NH3 1.24 0.42 0.86 
T6 19.50 Yes Rb 0.90 0.18 0.25 0.88 0.11 0.13 
T7 24.50 Yes Rb/NH3 0.77 0.37 0.14 0.76 0.39 0.19 
*Dog T5 did not have risk zone involvement of the subepicardial layer. Collat = developed collateral flow, significantly reducing the zone at risk; MBF = 
myocardial blood flow; NH3 = nitrogen-13 ammonia; PET = positron emission tomography; Post = postocclusion; Pre Occl = preocclusion; Rb = rubidium-82; 
RZ = risk zone; Wt = weight. 
study groups were observed at any of these times. Both 
heart rate and systolic arterial blood pressure remained 
stable throughout the study period. Synchronized retroper-
fusion did not significantly affect heart rate or blood pressure 
and did not produce significant arrhythmias. 
The retroperfusion pump flow averaged 54 ± 13 mUmin at 
the time of the flow tracer image and 60 ± 18 mUmin at the 
time ofF-18 deoxyglucose injection (Table 2). Peak coronary 
sinus pressures averaged 48 ± 21 mm Hg at the time of the 
retrograde perfusion scan; the corresponding minimal coro-
nary sinus pressure was 11 ± 7 mm Hg. At the time of the 
F-1S deoxyglucose scan, maximal coronary sinus pressure 
was 60 ± 24 mm Hg and minimal pressure was 8 ± 9 mm Hg. 
Thus, retroperfusion flow was constant throughout the study 
period. 
Arterial blood glucose, lactate and free fatty acid levels 
were similar for both groups of dogs before and after 
occlusion, as well as at the time of the F-18 deoxyglucose 
injection. Significant increases in free fatty acid levels were 
observed in both groups throughout the study period 
(Table 2). 
Microsphere blood ftow in normal and ischemic myocar-
dium (Table 3). Myocardial blood flow at rest in the risk 
zone before coronary occlusion was slightly lower in the 
treatment group (51.8 ± 8.4 mllmin per 100 g) than in the 
control group (68.33 ± 8.42 mllmin; p < 0.01). The magni-
tude of the flow reduction in myocardium distal to the 
coronary ligation was expressed as the ratio of average 
microsphere blood flow in risk zone to normal myocardium 
(Table 3). This ratio decreased in the control dogs from 
0.82 ± 0.22 before occlusion to 0.17 ± 0.07 at 15 min after 
coronary occlusion. These ratios were similar in the inter-
vention group, where they averaged 0.81 ± 0.1 before 
occlusion and decreased to 0.25 ± 0.1 at 15 min after 
occlusion. Repeat measurements of microsphere blood flow 
at 2 h after coronary occlusion demonstrated that blood flow 
remained depressed in risk zone myocardium as shown by 
an average risk zone to normal zone flow ratio of 0.28 ± 0.11 
in the treatment group and of 0.24 ± 0.09 in the control 
group. Thus, there were no significant intergroup differences 
or changes in transmural blood flow during the 2 h after 
occlusion. Epicardial blood flow at 2 h after occlusion was 
similar in the treatment and control groups. In the suben-
docardiallayer of the risk zone, residual flow in the treat-
ment group was slightly higher (0.32 ± 0.26) than in the 
control group (0.13 ± 0.05; p < 0.05). 
Positron Emission Tomographic Data 
Evaluation of myocardial blood ftow (Table 4). Visual 
analysis of the cross-sectional images demonstrated reten-
tion of the retrogradely delivered flow tracer in the risk zone 
in each of the seven treatment dogs and thus indicated 
effective retrograde delivery of blood flow by synchronized 
retroperfusion. Figure 2 shows an example of myocardial 
uptake of rubidium-82 after retrograde injection of the trac-
er; it depicts blood flow images acquired at baseline study, at 
15 min and at 85 min after coronary occlusion. Anterograde 
Table 2. Hemodynamic Data, Retroperfusion Flows and Coronary Sinus Pressures in the Two GlOupS (n = 13) 
Plasma Free Fatty Acid Levels 
Baseline 15 Min Post SRP Pump Flow 'CSP 120 Min Post (mEqlliter) 
HR SBP DBP HR SBP DBP 
(mVmm) (mm Hg) 
HR SBP DBP Pre 15 Min 120 Min 
Dog No. Wt(kg) (beats/min) (mmHg) (mmHg) (beats/min) (mmHg) (mmHg) EarlylLate Early/Late (beats/min) (mmHg) (mmHg) Occ! Post Post 
Control group 
C1 27 110 75 60 110 75 60 115 80 60 
C2 19 120 125 110 105 125 100 100 125 100 0.11 0.28 0.28 
C3 20 140 125 80 140 125 75 110 125 75 0.03 0.18 0.56 
C4 26 150 80 50 130 100 60 80 115 85 0.19 0.50 0.74 
C5 26 140 170 120 155 130 100 140 125 100 0.32 0.40 0.40 
C6 29 80 120 90 90 115 85 115 135 100 0.47 0.46 0.87 
Mean 24.2 123 116 85 122 112 80 110 118 87 0.22 0.36 0.57 
SD 4.1 26 35 27 24 21 18 20 19 17 0.17 0.13 ,0.24* 
P value' NS NS NS NS NS NS NS NS NS NS NS NS NS 
Treatment group 
Tl 26 125 105 80 150 75 50 60 65 120 110 60 
T2 37 165 95 70 165 83 55 60 60 170 76 50 0.32 0.30 0.38 
T3 32 108 100 80 94 100 80 72 92 30/4 38/0 118 105 75 0.46 0.30 0.65 
T4 25 160 123 93 98 124 95 60 65 44/5 50/0 100 130 100 0.00 0.00 0.00 
T5 22 64 125 83 78 128 96 49 56 55/14 62/13 80 104 81 0.46 0.59 0.59 
T6 20 105 125 105 126 125 100 40 51 84/22 100/20 116 100 75 0.31 0.36 0.58 
T7 25 130 140 115 126 142 115 34 34 46/5 52/6 95 146 105 0.07 0.12 0.41 
Mean 26.6 122 116 89 120 111 84 54 60 52/10 60/8 114 110 78 0.27 0.28 0.44 
SD 6 35 16 16 31 25 24 13 18 20/8 24/9 29 22 20 0.20 0.17 0.23§ 
P value' <0.05 NSt 
*p values refer to differences between treatment and control groups. tDenotes comparison between early and late synchronized reperfusion (SRP) pump variables. ;Mean values significantly higher (p < 0.02) than at 
preocc!usion control study. §Difference from preocC!usion levels statistically significant (p < 0.025). CSP = coronary sinus pressure; DBP = diastolic blood pressure; HR = heart rate; SBP = systolic blood pressure; other 
abbreviations as in Table 1. 
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Table 3. Risk Zone to Normal Zone Ratios* of Myocardial Blood Flow Determined by Microspheres in I3 Dogs 
Transmural Epicardial Endocardial 
MBF Ratio MBF Ratio MBF Ratio 
Dog No. Pre Occl 15 Min Post 120 Min Post Pre Occl 15 Min Post 120 Min Post Pre Occl 15 Min Post 120 Min Post 
Control group 
Cl 0.91 0.19 0.20 1.09 0.32 0.36 0.77 0.08 0.06 
C2 0.70 0.19 0.37 0.66 0.31 0.68 0.71 0.09 0.20 
C3 1.04 0.07 0.10 1.05 0.06 0.12 1.02 0.08 0.09 
C4 0.84 0.13 0.23 0.96 0.18 0.33 0.75 0.08 0.14 
C5 0.44 0.17 0.24 0.40 0.26 0.39 0.46 0.11 0.13 
C6 0.99 0.28 0.27 1.34 0.39 0.44 0.74 0.19 0.17 
Mean 0.82 0.17 0.24 0.92 0.25 0.39 0.74 0.11 0.13 
SD 0.22 0.07 0.09 0.34 0.12 0.18 0.18 0.04 0.05 
Treatment group 
T1 0.74 0.17 0.21 0.69 0.24 0.24 0.78 0.11 0.18 
T2 0.84 0.19 0.34 0.88 0.19 0.36 0.80 0.18 0.32 
T3 0.92 0.20 0.28 0.91 0.32 0.40 0.92 0.11 0.18 
T4 0.67 0.38 0.47 0.52 0.36 0.54 0.80 0.39 0.41 
T5 t t t t t t 1.24 0.42 0.86 
T6 0.90 0.18 0.25 0.93 0.29 0.37 0.88 0.1] 0.13 
T7 0.77 0.37 0.14 0.79 0.36 0.08 0.76 0.39 0.19 
Mean 0.81 0.25 0.28 0.79 0.29 0.33 0.88 0.24 0.32 
SD 0.1 0.1 0.11 0.16 0.07 0.16 0.17 0.15 0.26 
p value* NS NS NS NS NS NS NS <0.05 NS 
*Blood flow ratios are given for transmural blood flow and blood flow to the subepicardial and subendocardial half of the left ventricular myocardium. tDog 
T5 did not have epicardial segments in the risk zone. tp values refer to differences between treatment and control groups. Abbreviations as in Table I. 
blood flow to the territory distal to the left anterior descend-
ing coronary artery occlusion is markedly depressed and, as 
shown by the repeat study at 85 min, remained reduced 
throughout the experiment. Injection of tracer into the 
retroperfusion system resulted in preferential uptake of 
activity in the risk zone and demonstrated that nutrient 
blood flow was effectively delivered to the ischemic myocar-
dium. There was also some uptake of tracer in normal 
myocardium, most likely because of escape of part of the 
tracer dose from the coronary sinus into the systemic 
circulation and subsequent delivery to normal myocardium. 
Retrograde delivery of blood flow was demonstrated with 
rubidium-82 in three dogs and with N-l3 ammonia in the 
Table 4. Ratios of Blood Flow in Risk Zone to Normal 
Myocardium Determined From Cross-Sectional Positron Emission 
Tomographic Images in 11 Dogs 
Treatment Group 
Control Group 
Dog Retrograde 
Dog No. No. Perfusion 
C2 0.74 T1 0.61 5.55 
C3 0.54 T2 0.62 3.32 
C4 0.52 T3 0.77 1.13 
C5 0.33 T4 0.45 0.72 
C6 0.43 T6 0.39 1.64 
T7 0.59 0.70 
Mean ± SD 0.50 ± 0.15 0.57 !±! 0.14 2.18 ± 1.92 ! 
I I 
! 
P = NS p < 0.05 
Dog Cl did not have images of flow tracers. 
other four dogs. In achieving adequate retrograde delivery of 
blood flow to the risk zone, one of the dogs (Dog T6, Table 
2) attained a coronary sinus diastolic pressure of 100 mm Hg 
despite a flow rate of only 40 mUmin. 
Anterograde delivery of flow tracer to the myocardium at 
risk was evaluated from the circumferential activity profiles 
derived from the cross-sectional images of the left ventricu-
lar myocardium after anterograde administration of either 
N-l3 ammonia or rubidium-82. The ratio of activity concen-
trations in risk zone to normal myocardium averaged 0.50 ± 
0.15 in the control dogs and was similar to the ratio of 0.57 ± 
0.14 in the treatment dogs (p = NS) (Table 4). Relative 
uptake of the flow tracer after retrograde delivery was 
considerably higher in the risk zone than in normal myocar-
dium in the intervention dogs. Circumferential profile anal-
ysis of the blood flow images acquired after retrograde 
delivery of tracer in the treated dogs demonstrated a ratio of 
risk zone to normal zone of 2.18 ± 1.92 compared with 
0.57 ± 0.14 after anterograde delivery of flow tracer in the 
same dogs (p < 0.05). Visual analysis of the images obtained 
after flow tracer administration late in the study before F-18 
deoxyglucose injection in the intervention group and in all 
except for Dog Cl in the control group showed that the area 
of the risk zone had not changed from the time of the 
immediate postocclusion scan. 
Evaluation of glucose uptake (Table 5). Fluorine-18 de-
oxyglucose was injected 136 ± l3 min after coronary ligation 
in the control group and at 120 ± 14 min in the treatment 
group (p = NS) and image acquisition began 40 min after 
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Occlusion 
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Retro· 
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tracer administration in both groups. One of the intervention 
dogs (Dog Tl) did not have images of myocardial F-IS 
deoxyglucose uptake because the available activity was 
inadequate for external imaging. In this dog, regional myo-
cardial F-IS deoxyglucose tissue concentrations were deter-
mined by in vitro counting. 
Visual analysis of the images revealed normal or in-
creased tracer uptake in the risk zone in the six intervention 
Table 5. Uptake of F-18 Deoxyglucose in Risk Zone Relative to 
Normal Myocardium Determined by In Vitro Counting and 
Positron Emission Tomographic Images 
In Vitro Measurements 
In Vivo 
Dog No. Epi Endo Transmural PET 
Control group 
CI 1.22 0.27 0.75 N/A 
C2 0.56 0.29 0.41 0.66 
C3 0.24 0.14 0.18 0.68 
C4 0.49 0.25 0.36 0.52 
C5 0.49 0.13 0.28 0.37 
C6 2.48 0.76 1.54 1.79 
Mean 0.91 0.31 0.59 0.80 
SD 0.84 0.23 0.51 0.57 
Treatment group 
TI 1.86 1.30 1.54 NiA 
T2 1.91 0.91 1.27 1.16 
T3 1.39 0.83 1.08 1.62 
T4 1.00 0.70 0.84 0.94 
T5 1.11 1.12 1.25 NiA 
T6 0.66 0.26 0.44 0.80 
T7 1.75 1.34 1.52 1.04 
Mean 1.38 0.92 1.13 1.11 
SD 0.48 0.38 0.39 0.31 
p value* NS <0.01 <0.05 NS 
*p values refer to differences between treatment and control groups. 
Values are expressed as ratios of activity concentrations in the risk zone 
compared with those in normal myocardium. Endo and Epi = endomyocardial 
and epicardial layer of the left ventricular myocardium, respectively; PET = 
positron emission tomography. 
Ante· 
Grade 
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Figure 2. Retroperfusion flow. Images in three 
planes (1 to 3) are displayed. After left anterior 
descending coronary artery (LAD) occlusion, a 
defect is seen in each of the three planes (arrows). 
After retrograde infusion of the flow tracer rubid· 
ium-82 through the catheter in the coronary sinus, 
its uptake can be clearly seen in the risk zone of 
each plane. Uptake ofthe tracer was greatest in the 
risk zone, with only a small amount of the infused 
dose reaching the normal zone. After 85 min of 
coronary artery occlusion, repeat anterograde in-
travenous injection of rubidium-82 (Ante-Grade) 
revealed that the size of the risk zone had not 
changed appreciably in that time and that the 
resultant fate of the jeopardized zone would de-
pend on the effectiveness of retroperfusion. 
dogs that underwent imaging. An example of glucose uptake 
in an intervention dog is shown in Figure 3, where the three 
imaging planes demonstrate greater uptake of F-lS deoxy-
glucose in the risk zone than in the normal zone. Fluorine-IS 
deoxyglucose uptake was relatively low in the risk zone in 
the dog that required higher than usual coronary sinus 
pressures to delineate delivery of the flow tracer to the risk 
zone (Dog T6, Table 5). In contrast, in five of the six control 
dogs, glucose uptake in the risk zone was significantly lower 
than in the normal zone. The risk zone to normal zone F-IS 
deoxyglucose ratio was observed to be high in one of the six 
control dogs. In this dog, F-18 deoxyglucose uptake in the 
nonischemic zone was remarkably low. Fluorine-IS deoxy-
glucose uptake in the risk zone in a control dog is shown in 
Figure 4. Anterograde flow tracer injections demonstrated 
that there was no change in the size of the risk zone during 
the 2 h ofleft anterior descending coronary artery occlusion. 
At 3 h of occlusion, F-18 deoxyglucose uptake was consid-
erably lower in the risk zone than in the normal zone. 
Circumferential profile activity analysis of the F-18 de-
oxyglucose images revealed a risk to normal zone activity 
ratio of 0.8 ± 0.57 in the control group and 1.11 ± 0.31 in the 
treatment group (Table 5). Comparison of the circumferen-
tial profiles for myocardial F-18 deoxyglucose and flow 
tracer activity (either N -13 ammonia or rubidium-82) after 
retrograde delivery of either tracer suggested a linear rela-
tion of tracer concentration in myocardium at risk. For 
example, in the areas of good retrograde delivery of the flow 
tracer, the later uptake of F-18 deoxyglucose was either 
normal or increased. Conversely, where retrograde flow 
tracer delivery was poor (Dog T6), uptake of F-18 deoxyglu-
cose was also diminished. 
In vitro measurements of regional myocardial F-18 de-
oxyglucose activity revealed findings similar to the tomo-
graphically obtained data. As demonstrated by the risk zone 
to normal zone activity ratios, F-18 deoxyglucose uptake 
was transmurally decreased in the risk zone in the control 
JACC Vol. 18, No.1 
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Figure 3. Fluorine-18 deoxyglucose eSFDG) uptake in the treat-
ment group. The three planes reveal the creation of a risk zone 
after left anterior descending coronary artery occlusion. After 
retroinfusion ofthe flow tracer rubidium-82, its uptake can be seen 
in the risk zone. A late anterograde intravenous injection of the 
flow tracer nitrogen-13 ammonia (Ante-Grade) revealed that the 
size of the risk zone had not changed since left anterior descending 
coronary artery occlusion and thus any activity seen in the risk 
zone would have to occur by means of the retrograde route. 
Subsequent infusion of F-18 deoxyglucose showed that the risk 
zone was taking up this tracer and would likely have a high percent 
viability. 
dogs by an average of 41 % relative to normal myocardium 
but was 13% higher than in normal myocardium in the 
treatment group (p < 0.05) (Fig. 5, Table 5). Although a 
similar tendency was observed for the outer (epicardial) half 
of the left ventricular myocardium, this difference in tracer 
uptake was not statistically significant. In contrast, F-18 
deoxyglucose concentrations were significantly lower in the 
endocardial than in the epicardial half of the left ventricular 
myocardium in the control dogs. Endocardial F-18 deoxy-
glucose uptake was approximately three times higher in the 
treatment than in the control group (risk zone to normal zone 
Figure 4. Fluorine-18 deoxyglucose eSFDG) uptake in the control 
group. After left anterior descending coronary artery occlusion, 
there was the creation of a risk zone in all three planes (l to 3). After 
liS min of occlusion, repeat injection of the flow tracer nitrogen-13 
ammonia (\3NH3) revealed no change in the size of the risk zone. At 
175 min of occlusion, the images of F-18 deoxyglucose uptake 
showed little or no risk zone uptake of this tracer, suggesting a low 
potential percent viability of the risk zone. 
18FDG 
170 min 
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+170 min 
myocardial ratio 0.92 ± 0.38 vs. 0.31 ± 0.23; p < 0.01) (Fig. 
5, Table 5). 
Histochemical Analysis 
The dogs were killed at an average of 194 min after 
occlusion of the left anterior descending coronary artery. 
The time interval from occlusion to induced death averaged 
206 ± 9 min for the control dogs and 180 ± 18 min for the 
treatment group (p < 0.01). The size of the risk zone, defined 
as the area with a 2:50% decrease in microsphere-measured 
blood flow relative to normal myocardium, averaged 29.4 ± 
21.4% in the treatment group. Although this value tended to 
be lower than the corresponding value of 36.73 ± 9.35% in 
the control group, this difference failed to attain statistical 
significance. In the analysis of glycogen staining, the relative 
area of glycogen depletion averaged 27.07 ± 17.10% in the 
treatment group and 41.23 ± 11.80% in the control group 
(p = NS). 
Adequate triphenyltetrazolium chloride staining was ac-
complished in six treatment and five control dogs. Areas 
unstained by triphenyltetrazolium chloride were expressed 
as a percent of the risk area and averaged 18.4 ± 22.6% in 
the treatment group. They were thus significantly smaller 
than in the control group, in which these areas averaged 
61.16 ± 25.41% (p < 0.02) (Fig. 5, Table 6). 
Discussion 
Aims ofthe study. This study indicates for the first time in 
an in vivo model in experimental animals that synchronized 
retroperfusion can result in effective retrograde delivery of 
nutrient blood flow to acutely ischemic myocardium. As 
evidenced with F-18 deoxyglucose uptake, effective retro-
grade delivery of blood flow probably accounted for the 
observed augmentation of metabolic activity in the ischemic 
myocardium in the intervention group. This in turn may have 
prevented or delayed progression of ischemia to necrosis as 
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Figure 5. Postmortem analysis and in vitro F-18 deoxy-
glucose (FDG) counts. Risk zone size measured by refer-
ence to microsphere-derived myocardial blood flow was 
similar in both groups, Infarct size measured by triphe-
nyltetrazolium chloride nonstaining was similar in the 
control (Cx) and treatment (Rx) groups. However, when 
percent infarction was assessed by relating infarct size to 
the size of the risk zone, it was significantly smaller in the 
treatment than in the control group. In vitro counting of 
F-18 deoxyglucose in transmural samples revealed a sig-
nificantly greater risk zone to normal zone count ratio in 
the intervention group than in the control group after 3 h 
of retroperfusion. 
ex Rx 
Risk 
Zone 
ex Rx 
Infarct 
Zone 
ex Rx 
Percent 
Infarct 
ex Rx 
Total 
In-Vitro FOG 
demonstrated by significantly smaller areas unstained by 
triphenyltetrazolium chloride in the acutely ischemic myo-
cardial regions in the treatment dogs. 
This study was designed to address several aspects of the 
concept of synchronized retroperfusion. The first was to 
attempt to visualize tomographically the delivery of a flow 
tracer to risk zone myocardium under conditions of retro-
Table 6. Risk Zone and Infarct Zone Determined by Postmortem 
Analysis of Myocardial Cross Sections 
Glycogen Non-TIC 
RZMBF Depletion Staining % 
Dog No. (%) (%) (%) INFIRZ 
Control group 
Cl 32.86 34.43 15.55 43.04 
C2 33.56 28.60 N/A N/A 
C3 52.29 62.50 45.19 73.61 
C4 25.87 42.51 29.65 100.00 
C5 42.84 43.34 20.53 49.11 
C6 32.95 36.00 17.20 40.06 
Mean 36.73 41.23 22.03 61.16 
SD 9.35 11.80 14.00 25.41 
Treatment group 
T1 34.82 58.40 00.00 00.00 
T2 31.40 16.60 N/A N/A 
T3 53.33 25.00 15.99 29.98 
T4 22.95 27.64 3.46 15.08 
T5 1.20 6.46 00.00 00.00 
T6 56.61 38.50 33.10 58.47 
T7 5.80 16.91 0.41 7.07 
Mean 29.44 27.07 8.83 18.43 
SD 21.40 17.10 13.40 22.60 
p value* NS NS =0.06 <0.02 
*p values refer to differences between treatment and control groups. Risk 
zones (RZ) expressed as the average percent of normal myocardium were 
determined by >50% reduction in myocardial blood flow (MBF) or by 
glycogen depletion and the area of triphenyltetrazolium chloride (TIC) 
nonstaining. Area unstained by triphenyltetrazolium chloride expressed as 
percent risk was determined by reduced myocardial blood flow. %INFIRZ = 
percent infarction of the risk zone. 
grade flow and coronary sinus pressures that were likely to 
be used clinically. To achieve this, a risk zone would need to 
be created that would not be so small that the retrograde 
delivery of a flow tracer could not be distinguished from 
surrounding myocardium or so large that the dogs would not 
survive. Another aspect was to monitor the amount of 
residual flow to the risk zone and its size during the period of 
coronary occlusion. This was done by examining a late 
(120 min) flow tracer injection and recording risk zone and 
normal zone myocardial blood flow with microspheres. The 
next step was to examine the metabolic activity of the risk 
zone, for which F-18 deoxyglucose was chosen as the tracer 
because ischemic dog myocardium preferentially takes up 
this tracer. A 3 h occlusion was chosen as the period of 
investigation rather arbitrarily, but also as the period that 
would most likely be required to stabilize and prepare a 
patient for definitive management. To confirm that the risk 
zone would truly have been made ischemic, the area of 
glycogen depletion appearing on myocardial cross sections 
was assessed. 
Technical limitations. Although an attempt was made to 
replicate the clinical situation as much as possible, there 
were several technical aspects to consider in assessing the 
experiment. For logistic reasons, the total time required for 
anesthesia and preparation before left anterior descending 
coronary artery occlusion was 120 min in the control group 
and 180 min in the intervention group. The effect that this 
might have had on the hemodynamics and eventual infarct 
size in both groups of dogs, but particularly in the treatment 
group, may be significant. Catheter position during retro-
perfusion is usually optimized with fluoroscopy, but this was 
not readily available during the experiment. Under usual 
clinical circumstances, fluoroscopy would be an integral part 
of the optimization of catheter position within the coronary 
sinus in relation to optimal risk zone perfusion. In this 
experiment, the use of the open chest model was necessary 
to assist in positioning of the animal for imaging purposes 
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and in controlling many aspects of the intervention. A closed 
chest approach might have yielded better results. 
Evaluation of myocardial blood flow. Synchronized ret-
roperfusion was shown to deliver nutrient blood flow retro-
gradely to risk zone myocardium after experimental acute 
coronary occlusion. With the addition of either rubidium-82 
or N-13 ammonia to the retroperfusate, uptake of the flow 
tracer was seen in the myocardium at risk after acute left 
anterior descending coronary artery occlusion. Both tracers 
of blood flow have been shown (11-13) to accurately delin-
eate myocardial tissue perfusion over a wide range of 
physiologic conditions. In contrast to other flow tracers such 
as Renografin or microspheres, the uptake of a positron-
emitting flow tracer indicates metabolic trapping of that 
tracer in the zone of interest. The uptake of the flow tracers 
in the risk zone was higher than that in the normal zone in 
most cases, demonstrating that the retrograde route was 
responsible for flow delivery to the risk zone. Repeated 
injections of the flow tracers in the animals late in the 
postocclusion period did not reveal changes in the size of the 
risk zone or an increase in residual risk zone flow, indicating 
that increased collateral blood flow did not account for 
augmented perfusion. This was further confirmed by the 
microsphere measurements that demonstrated that antero-
grade blood flow to the risk zone did not increase signifi-
cantly with time after occlusion. 
Retroperfusion flow and catheter placement. The position 
of the retroperfusion catheter is critical in obtaining flow to 
the risk zone myocardium. In this model, the catheter was 
located quite distally in the great cardiac vein so that the 
stroke output could perfuse the risk zone within each cardiac 
cycle. The position of the catheter needs to be adjusted so 
that in cardiac systole and with active deflation of the 
diastolically inflated balloon, there is free egress of venous 
blood into the coronary sinus. In addition to the position of 
the catheter within the coronary sinus, other major determi-
nants of effectiveness of delivery of the flow tracer include 
the flow rate from the pump and the pressure generated 
during the pumping cycle. It appears that flow rates between 
54 and 62 mllmin combined with coronary sinus diastolic 
pressures of 48 ± 23 to 60 ± 20 mm Hg achieved a significant 
delivery of flow tracer to the risk zone. The individual 
retroperfusion pressure and flow data in Table 2 show that 
the flow rates achieved (40 to 72 mllmin) were low, but in 
most cases they were the maximal flow rates that the pump 
could achieve. Since the completion ofthis study, the pump 
design has been modified so that blood flow can be delivered 
retrogradely at higher flow rates and this should provide 
better results with retroperfusion. As the pumping pressure 
per unit of time is increased, the danger of rupture of the 
coronary sinus would appear to increase. No damage to the 
myocardial risk zone, normal myocardium, the anterior 
interventricular vein, great cardiac vein or coronary sinus 
was observed with the pumping variables used in this study. 
The retrograde delivery of the flow tracer invariably 
resulted in its being taken up preferentially in the risk zone 
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myocardium. Why this occurred is of interest. In experi-
ments (20,21) in which krypton-85 and xenon-133 injections 
were administered through the coronary venous system in an 
experimental model designed to analyze the residual antero-
grade flow of coronary artery occlusion, the uptake of these 
tracers was found to be greatest in the area in the risk zone 
created by left anterior descending coronary artery occlu-
sion. Conversely, if an anterograde perfusion deficit was not 
created, the uptake of these tracers was uniform in the left 
circumflex and left anterior descending coronary artery 
territories. The explanation appears to be that uptake of the 
retrogradely injected isotope tended to be greatest in the 
area of least resistance. The least resistance was found in the 
bed of the coronary artery that had been occluded (20,21). 
Glucose metabolism. Augmented F-18 deoxyglucose up-
take relative to either reduced blood flow or normal myocar-
dium has previously been shown (22,23) to accurately iden-
tify viable myocardium. Tissues subjected to severe 
ischemia but still showing augmented glucose uptake can be 
identified by relatively increased F-18 deoxyglucose uptake 
compared with nonischemic myocardial tissue. Conversely, 
reduced glucose uptake in proportion to blood flow implies a 
significant amount of necrosis in the risk zone (24). This 
framework of reference was used to identify viable and 
nonviable tissue in the setting of acute coronary occlusion 
and synchronized retroperfusion. 
Uptake of F-18 deoxyglucose. This experimental model 
created a coronary occlusion that was associated with 60% 
necrosis of the risk zone in the control experiments. The 
findings revealed a significant reduction in the uptake of F-18 
deoxyglucose in the risk zone relative to intact myocardium 
because the majority of myocytes in this zone were irrevers-
ibly damaged and devoid of glucose utilization. With retro-
grade delivery of flow to the jeopardized zone, the uptake of 
F-18 deoxyglucose was found to be normal or increased 
relative to that in normal myocardium. In vitro determina-
tions of myocardial F-18 deoxyglucose uptake suggested a 
significantly greater utilization of glucose in the intervention 
group than in the control group. Comparison of the image 
and in vitro data demonstrates comparable values for the 
myocardial distribution of F-18 deoxyglucose uptake. Unlike 
the in vitro measurements, however, the difference of F-18 
deoxyglucose uptake as determined from the positron emis-
sion tomographic images did not achieve statistical signifi-
cance. This was so for a number of reasons. One control dog 
that did not have F-18 deoxyglucose imaging was not in-
cluded in the analysis of the image data. In this animal (dog 
C1), the in vitro F-18 deoxyglucose risk zone to normal zone 
ratio was low and the eventual percent infarction in the risk 
zone was high. The positron emission tomographic F-18 
deoxyglucose image comparison also did not include the 
data of two intervention animals (Dogs T1 and T5) that had 
a high in vitro F-18 deoxyglucose risk zone to normal zone 
uptake ratio and that showed no necrosis on triphenyltetra-
zolium chloride staining. It is possible that this comparison 
would have been significant if the data from these dogs had 
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been included. Nonetheless, when available, the tomo-
graphic images were useful in providing in vivo information 
about the metabolic activity of the jeopardized myocardium. 
Subepicardial versus endocardial glucose utilization rates. 
Although subepicardial glucose utilization rates were similar 
in both groups of dogs, glucose uptake in the endocardial 
layer was significantly higher in the intervention than in the 
control group. Subepicardial flow could have been main-
tained by collateral flow in both groups. However, flow to 
the subendocardium is usually reduced most severely after 
coronary occlusion. Residual blood flow, although slightly 
less in the control group, was markedly reduced in both the 
control and the intervention groups at 15 min after left 
anterior descending coronary artery occlusion. This reduc-
tion was maintained at 120 min of occlusion. Such a reduc-
tion in risk zone flow is usually associated with a high 
percent infarction of jeopardized myocardium (25,26). How-
ever, in this study, the subendocardial uptake of F-18 
deoxyglucose in the risk zone was significantly higher in the 
intervention group than in the control group. This finding 
indicated that a significantly greater area of myocardium in 
the risk zone had remained metabolically active and thus 
viable because of retroperfusion. Furthermore, the percent 
necrosis of the risk zone in the intervention group was only 
18.4%, which implied that a large number of myocytes were 
viable and continued to remain metabolically active. 
The major difference between the two groups that led to 
the differences in glucose uptake appeared to be the retro-
grade delivery of flow in the intervention group. The amount 
of this flow could not be quantified in this model, but it was 
clearly enough to make a difference both in glucose utiliza-
tion and in eventual percent infarction of the risk zone. The 
utilization of glucose at the myocardial level can be quanti-
fied by reference to an arterial input function. However, this 
could not be obtained in our study because it was not 
possible to place the input function in the coronary sinus, 
which in this model was also the delivery route for F-18 
deoxyglucose. 
One of the control dogs (Dog C6) exhibited a marked 
increase in F-18 deoxyglucose uptake the in risk zone 
relative to normal myocardium. Because tracer uptake and 
regional glucose metabolic rates could not be quantified in 
this study, it remains uncertain whether this relative increase 
reflected an absolute increase in glucose metabolic rate in 
the risk zone relative to that in the nonischemic zone. Blood 
flow to the risk zone myocardium as determined by micro-
spheres did not improve over time in this dog. Thus, 
spontaneous reperfusion with collateral blood flow is un-
likely to explain the enhanced F-18 deoxyglucose uptake. A 
more likely explanation is that glucose utilization in the 
nonischemic myocardium, as was observed by visual analy-
sis of the F-18 deoxyglucose scans, was low, possibly 
because of low insulin and high free fatty acid levels (Table 
2). As a result, the relative amount of F-18 deoxyglucose in 
the risk zone appears to be much greater than in the 
nonischemic myocardium, thus accounting for an apparently 
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high risk zone to normal zone ratio. In quantitative terms, 
this uptake was likely to have been small as shown by the 
large area (40%) of risk zone myocardium that did not stain 
with triphenyltetrazolium chloride. 
Histochemistry. The risk zone determined from measure-
ments of microsphere blood flow was similar in both groups. 
The glycogen-depleted area is different from the micro-
sphere-derived risk zone as evidenced by the observation 
that only slices 2 and 4 could be used for the glycogen 
analysis. Histochemical evidence of glycogen depletion is 
useful in confirming that the area of interest has indeed been 
made ischemic as a result of coronary artery occlusion (27). 
Table I indicates a considerable variation in both the extent 
of the initial perfusion defect, as measured both by positron 
emission tomography and by microsphere-derived blood 
flow, and the degree of reduction in residual flow to the risk 
zone. Some dogs apparently achieved no defect after left 
anterior descending coronary artery occlusion, whereas oth-
ers had a considerable defect. Some dogs appeared to 
develop collateral flow early and others did not. Minimal 
defect size and early collateralization might be associated 
with minimal reduction in glycogen staining, whereas in the 
dogs included in the study, there was considerable reduction 
in the extent of glycogen staining and the extent of this 
depletion was similar in both groups of animals (Table 6). 
Retroperfusion is unlikely to have had a significant impact on 
the area of glycogen depletion. In an experiment that al-
lowed 24 h of reperfusion after a 3 h coronary occlusion in 
the dog model, the area of glycogen depletion was unlikely to 
have undergone any repletion because of the extent to which 
exogenous glucose was converted to lactate (28). 
Triphenyltetrazolium chloride staining. The limitation of 
the percent infarction of the risk zone indicated by the area 
unstained by triphenyltetrazolium chloride in the interven-
tion group was substantially greater than that in the control 
group. Although this effect has been observed previously 
(2,4) this study demonstrates that it was most likely achieved 
by retroperfusion and would not have been accounted for by 
a very small or nonexistent postocclusion defect or the 
development with time of collateral flow to the risk zone. 
The utilization of triphenyltetrazolium chloride staining as a 
measurement of the area of necrosis is open to some debate, 
particularly when there has been <6 h of coronary occlu-
sion. However, the evaluation was done at the same time in 
both the control and intervention groups. As a result, it is 
likely that the reliability of triphenyltetrazolium chloride as a 
marker of cellular necrosis is the same in both groups. The 
time to induced death was slightly longer (27 min) in the 
control than in the treatment group, but this difference is 
unlikely to explain the large difference in percent infarction 
observed between the groups (18.4 ± 22.6% in the treatment 
group and 61.16 ± 25.41% in the control group). In experi-
ments (25) designed to assess infarct size for up to 24 h of 
coronary occlusion, there was very little difference in infarct 
size when measured at 3 and 24 h. 
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Clinical implications. In situations where anterograde 
coronary flow cannot be rapidly reestablished with certainty 
after acute left anterior descending coronary artery occlu-
sion, synchronized retroperfusion might be considered as a 
means of maintaining viability of jeopardized myocardium, 
while definitive methods of reopening the artery are initi-
ated. Such situations might occur after sudden impenetrable 
occlusion of the artery during or after angioplasty and in the 
early period following coronary artery thrombosis, when the 
likelihood and timing of reestablishment of anterograde flow 
with thrombolysis or acute coronary angioplasty appear to 
be uncertain. 
The retroinfusion of many pharmacologic agents has 
been shown to be effective in limiting infarct size (4,29,30), 
achieving arrhythmia control (31) and cardioplegia (32,33) 
and attaining high concentrations of a beta-adrenergic block-
ing agent in the risk zone (34). The demonstration of retro-
grade blood flow tracer delivery directly to the risk zone by 
positron emission tomography can also be applied to the 
delivery of pharmacologic agents to the risk zone when 
injected retrogradely. It is possible that sufficient concentra-
tions of such agents delivered to the myocardial risk zone in 
combination with the retroperfusion of arterial blood might 
further protect the jeopardized myocardium in addition to 
the effects of arterial blood alone. 
Conclusions. In acute left anterior descending coronary 
artery occlusion, positron emission tomography using flow 
tracers demonstrated that synchronized retroperfusion can 
deliver arterial blood retrogradely to the risk zone myocar-
dium. The increased viability of the tissue at risk in the 
intervention group was predicted by evidence of metabolic 
activity, whereas in the control group a relative lack of 
metabolic activity predicted a large percent infarction of the 
jeopardized zone. The amount of retrogradely delivered flow 
is sufficient to produce improved viability of the risk zone as 
shown by the uptake of F-18 deoxyglucose and the limitation 
of infarct size by 70% in treated compared with control dogs. 
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